Compare Hut 8 Corp (HUT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Viatris Inc — how do they compare? Hut 8 Corp trades at $84.27 (market cap $9.82B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 2× Hut 8 Corp's market cap, and Viatris Inc pays a 2.75% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 11 Days and Viatris Inc for 57 Days on average.
| HUT | VTRS | |
|---|---|---|
Market Cap | $9.82B | $20.03B |
Volume | 10,272,678 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $133.02 | $18.27 |
52-Week Low | $33.76 | $9.74 |
Typical Hold Time | 11 Days | 57 Days |
Enterprise Value | $17.25B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $84.27, down 5.63% today, with a bearish technical outlook despite oversold RSI readings. The company reported negative earnings in recent quarters, missing expectations, with a net income margin of -188.59% for 2026. Recent positive developments include securing a $1.07 billion credit facility and analyst optimism around AI infrastructure contracts.
While analyst consensus is strongly bullish with a $162.69 price target, significant execution risks persist given negative profitability and cash flow challenges. The stock offers high potential upside if AI infrastructure contracts materialize but carries substantial risk from ongoing losses and competitive pressures in the digital infrastructure space.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
